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Summary: Primary cutaneous mucinous carcinoma (PCMC) is a rare mucin-producing malignancy derived from epithelial glandular structures. The literature regarding this topic is mostly in the form of case reports and case series. PCMC tends
to present in the elderly with predilection for the head and neck and on initial
assessment it can be easily mistaken for a simple inclusion cyst. Although PCMC
is often indolent in nature, in rare instances it can metastasize and should remain
a differential diagnosis in a selected population. The significance in identifying
PCMC is reliably differentiating it from metastatic mucinous adenocarcinoma. We
present a review of literature and case of PCMC on the scalp of a 67-year-old female.
(Plast Reconstr Surg Glob Open 2018;6:e1761; doi: 10.1097/GOX.0000000000001761;
Published online 16 April 2018.)

P

rimary cutaneous mucinous carcinoma (PCMC) is a
rare mucin-producing malignancy derived from epithelial glandular structures, first described in 1952
by Lennox et al.1–4 The tumor most often presents in the
sixth or seventh decade with a predilection for the head
and neck.5–7 It tends to locally recur, but rarely metastasizes.1,2,5 Since its initial description, literature documents
various case series and reports of PCMC. After identification of a cutaneous mucin-producing neoplasm, it is essential to differentiate the primary cutaneous form from
an underlying metastatic malignancy because the prognosis and management differ drastically.1–4

BACKGROUND

In 2005, Kazakov et al.5 published a series of mucinous
lesions, 37 of which were PCMC with 24 metastatic adenocarcinomas. The average age of presentation in this series
was 65.2 years. Of the 37 PCMC identified, 95% presented
on the head and neck and 41% were on the scalp. AddiFrom the *Department of Surgery, Division of Plastic and
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tionally, there are a few case series (Table 1) such as the
meta-analysis by Kamalpour et al.6 containing data from
1952 to 2010, which document 159 PCMC with the majority in the head and neck area.
One of the greatest challenges in identifying PCMC
is differentiating it from an underlying metastatic
process.2–5,8–10 The presentation of the primary cutaneous
form both histologically and grossly appears nearly identical to metastatic adenocarcinoma. The tumor cells may
stain positive immunohistochemically (IHC) for specific
markers of breast, lung, ovary, prostate, and gastrointestinal
(GI) tumors that will carry a poor prognosis.1–4 Research in
differentiating these processes via IHC markers has been
pursued. In a small series by Levy et al.,3 PCMC and breast
metastatic mucinous carcinoma to the skin stained positive for CK7, whereas primary colorectal adenocarcinoma
stained positive for CK20. Authors concluded that CK20
was an appropriate IHC marker to differentiate GI adenocarcinomas; however, the other markers were neither
sensitive nor specific enough to differentiate breast from
the primary cutaneous forms. Literature supports that the
presence of an in situ component favors PCMC, whereas
location on the chest wall or in the axilla tends to favor a
breast primary.5
In a 16-year retrospective study at a single cancer center, 51 cases of metastatic adenocarcinoma from an internal primary were identified.8 In the majority of them, the
cutaneous metastatic lesion presented within 3 years following initial diagnosis; however, in 6 cases, the cutaneous
metastasis was the initial presentation of an underlying
malignancy. These findings support the importance of a
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Table 1. PCMC in the Literature
Author
Breiting et al.2
Mendoza and Helwig4
Kazakov et al.5
Kamalpour et al.6
Al Beteddini et al.7
Choi et al.9
Hanna et al.10

Cases

Age Range
(Average)

Head
and Neck

Trunk/
Other

15

43–83 (64)

14

1

9
35
137

5
2
22

14
37
159
1
1
1

8–76 (51.3)
31–89 (65)
63.5
61
49
74

1
1
1

Outcomes
1 patient required chemotherapy for recurrence, 1 regional
lymph node metastasis
6 recurrences, 1 regional lymph node metastasis
7 reexcisions due to positive margins, 5 recurrences
15 treated with Mohs: 2 (13%) recurrences; 136 treated with
excision: 46 (34%) recurrences
Mohs surgery
5 mm excision margin, no recurrence
Recurrence following surgical excision, subsequently treated
with radiation

Fig. 1. Intraoperative excised scalp specimen revealing transition
between the skin and lesion.

thorough workup for underlying malignancy upon recognition of a cutaneous mucinous neoplasm.
Treatment modalities of PCMC include surgical excision or Mohs procedure, with local recurrence rates up to
40%.6 A poor outcome, defined by recurrence or metastasis, was associated with younger age at presentation, lesion
> 1.5 cm, and lesions presenting on the trunk.6 Alternatively, a favorable outcome was associated with individuals who
presented at an older age, with smaller lesions, and lesions
on the head and neck.6 In rare instances, radiation alone, or
in combination with chemotherapy, has been attempted in
patients with distant metastasis of PCMC with little success.6,10

Fig. 2. Hematoxylin and eosin staining 100× magnification of excised specimen.

CASE PRESENTATION

A 67-year-old Caucasian female with medical history of
inflammatory bowel disease presented for evaluation of an
enlarging, palpable scalp mass for the past year. She reports that in addition to growth, the lesion started to cause
migraine headaches. On physical examination, a mobile
mass measuring 5 × 3 cm was observed on the right temporal scalp region. The skin was thickened but no ulceration,
bleeding, or sinus tracts were appreciated. Based on clinical evaluation, the patient was scheduled for lesion excision and closure of a suspected epidermal inclusion cyst.
The patient was brought to the operating room for surgical excision of lesion. However, instead of revealing the
expected cyst wall, the opening incision revealed a pink,
nonwalled mucinous substance. Due to the unexpected
findings, the surgeon completed an excisional biopsy with
primary closure (Fig. 1).
Hematoxylin and eosin histologic examination revealed an infiltrative tumor center in the dermis and
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Fig. 3. Specimen showing CK 7-positive immunohistochemical
staining.

e xtending into the subcutis and margins of resection. The
tumor was composed of pools of mucin separated by thin
fibrous septae with mildly atypical epithelial clusters and
duct formation floating amongst the mucin (Fig. 2). IHC
analysis showed the tumor cells to be strongly CK7-positive
(Fig. 3) while CK 20-negative. Based on these findings, the
histologic differential diagnosis included PCMC versus
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metastatic mucinous carcinoma, especially of the breast
due to CK7 positivity. Therefore, the patient was referred
to oncology for a thorough oncologic workup.
Mammography showed no abnormalities, excluding
breast as primary; however, positron emission tomography
scan revealed hypermetabolic activity suspicious for rectal
adenocarcinoma. Following discussion with her gastroenterologist and oncologist, the increased activity observed
from the positron emission tomography scan was determined to be secondary to her history of inflammatory
bowel disease. This diagnosis was biopsy proven, thereby
ruling out a GI malignant primary. After discussion with
the pathologist, comprehensive assessment of IHC CK20negative staining further supported the excised lesion
as a PCMC. Literature on resection margins for PCMC
is scarce. The decision for margin reexcision was based
on management of malignant skin cancers.9,10 Reexcision
was performed with a 1.0-cm margin, leading to a 6 × 4 cm
defect that was closed via complex wound closure. The final pathology reported negative margins. The patient is 6
months postoperative with no recurrences and follows in
conjunction with oncology.

DISCUSSION

This case demonstrates the relatively rare phenomenon of PCMC presentation (estimated < 50 documented
cases with scalp presentation). PCMC should be in the
differential diagnosis of cutaneous lesions, specifically in
patients of older age with lesions of the head and neck. Literature describes metastatic cutaneous adenocarcinoma
with primary sites of malignancy in the lungs, breast, and
viscera. Although IHC stains aid in the workup of primary
cutaneous versus metastatic mucinous adenocarcinoma,
they should not be relied on exclusively to determine the
definitive diagnosis. Upon discovery of a cutaneous lesion
with histology, suggesting mucinous adenocarcinoma, a
thorough oncologic workup is warranted to rule out an
underlying malignancy. For the future, given the rarity of

this tumor, it is important to maintain continuous documentation especially regarding margin resection to track
outcomes such as recurrence and metastasis.
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